C Dalla Man, G Bock, PD Giesler, DB Serra, M … - Diabetes Care, 2009 - Am Diabetes Assoc RESULTS—Vildagliptin reduced postprandial glucose concentrations (905 ± 94
vs. 1,008 ± 104 mmol/6 h, P = 0.02). Vildagliptin did not alter net S I (7.71
± 1.28 vs. 6.41 ± 0.84 10 −4 dl · kg −1 · min −1 · μU −1 · ... Cited by 3 - Related articles - All 3 versions
A Vella, G Bock, PD Giesler, DB Burton, DB … - Clin Endocrinol (Oxf), 2008 - medscape.com Objectives: The incretin hormone glucagon-like peptide-1 (GLP-1) retards gastric
emptying and decreases caloric intake. It is unclear whether increased GLP-1
concentrations achieved by inhibition of the inactivating enzyme dipeptidyl ... Cited by 8 - Related articles - All 7 versions
SZ Duan, CY Ivashchenko, MG Usher, RM … - PPAR Research, 2008 - pubmedcentral.nih.gov Peroxisome proliferator-activated receptor- (PPAR- ), an essential
transcriptional mediator of adipogenesis, lipid metabolism, insulin sensitivity,
and glucose homeostasis, is increasingly recognized as a key player in ... Cited by 2 - Related articles - All 3 versions
KM Chu, OYP Hu, LH Pao, CH Hsiong - Journal of Pharmacy & Pharmaceutical Sciences, 2007 - ejournals.library.ualberta.ca J Pharm Pharmaceut Sci (www. cspsCanada.org) 10 (4): 411-419, 2007 ...
Pharmacokinetics of Oral Rosiglitazone in Taiwanese and Post Hoc Comparisons
with Caucasian, Japanese, Korean, and Mainland Chinese Subjects Cited by 2 - Related articles - View as HTML - All 3 versions
Y Lee, MK Kwon, ES Kang, YM Park, SH Choi … - Journal of Gene Medicine, 2008 - interscience.wiley.com Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that plays an
important role in glucose homeostasis. Its functions include glucose-stimulated
insulin secretion, suppression of glucagon secretion, deceleration of ... Cited by 2 - Related articles - BL Direct - All 4 versions
X Zhao, YM Cui, Y Zhou, HL Zhang, KP Yeo, H … - International journal of clinical pharmacology and …, 2008 - ncbi.nlm.nih.gov OBJECTIVES: Exenatide is an adjunctive treatment for Type 2 diabetes. This was
the first study to evaluate the pharmacokinetics, safety and tolerability of
therapeutic doses (5 microg and 10 microg) of exenatide after single and ... Cited by 2 - Related articles - All 2 versions
H Fuder, P Kleist, M Birkel, A Ehrlich, S … - European journal of clinical pharmacology, 1997 - Springer Abstract Objective: Voglibose is a new and potent in- hibitor of a-glucosidases
and is used for the treatment of diabetes mellitus. Since voglibose increases
gastrointes- tinal motility and could thus a ect absorption of con- ... Cited by 2 - Related articles - BL Direct - All 5 versions
FM Couto, AH Minn, CA Pise-Masison, M … - Metabolism-Clinical and Experimental, 2007 - biostat.wisc.edu Page 1. Exenatide blocks JAK1-STAT1 in pancreatic beta cells Francesca M. Couto
a , Alexandra H. Minn a , Cynthia A. Pise-Masison b , Mike Radonovich b , ... Cited by 2 - Related articles - View as HTML - All 16 versions
[CITATION] Diagnosis and Management of Type 2 Diabetes. Greenwich, CT: Professional …
